Aliskiren in Combination With Amlodipine in Hypertensive Patients Not Responding to Angiotensin Receptor Blocker (ARB) Plus Amlodipine

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the efficacy and safety of the single pill combination of Aliskiren and Amlodipine in patients with moderate hypertension not adequately responding to a single pill combination of Olmesartan and Amlodipine.

Further this study will also assess the efficacy and safety of a single pill combination of Aliskiren, Amlodipine and Hydrochlorothiazide (HCTZ) in patients with moderate hypertension not adequately responding to a single pill combination of Aliskiren and Amlodipine.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Angiotensin Receptor Antagonists; Olmesartan

Criteria

Inclusion Criteria:

• Essential hypertension stage II

• Male and female patients

• Age >= 18 years old

Exclusion Criteria:

• Severe hypertension (systolic BP >= 180 mmHg, diastolic BP >= 110 mmHg

• Poorly controlled diabetes mellitus or type 1 DM

• History of myocardial infarction, stroke

• Presence of heart failure

• Other protocol-defined inclusion/exclusion criteria may apply